Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$100.30
-0.67-0.66%
À la fermeture: -
$101.00
0.700.70%
Après les heures de négociation: 5:31 PM EDT
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
Boston Scientific Corp a un objectif de cours consensus de $119.74, basé sur les évaluations des 23 analystes. Le plus élevé est de $140 attribué par UBS le octobre 23, 2025, et le plus bas est de $78 attribué par Deutsche Bank le juillet 25, 2024. Les 3 dernières évaluations d'analystes ont été publiées par UBS, Truist Securities et Wells Fargo le octobre 23, 2025. Avec un objectif de cours moyen de $131.67 entre UBS, Truist Securities et Wells Fargo, il y a une variation implicite de 30.36% upside pour Boston Scientific Corp à partir de ces dernières évaluations d'analystes.
Sociétés d'analyse émettant des recommandations1
UBS
Truist Securities
Wells Fargo
Morgan Stanley
Canaccord Genuity
1calculé à partir des notes des analystes
Notes d'analystes pour Boston Scientific
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/23/2025 | 38.61% | UBS | $135 → $140 | Maintains | Buy | |||
10/23/2025 | 28.71% | Truist Securities | $129 → $130 | Maintains | Buy | |||
10/23/2025 | 23.76% | Wells Fargo | $124 → $125 | Maintains | Overweight | |||
10/23/2025 | 28.71% | Morgan Stanley | $125 → $130 | Maintains | Overweight | |||
10/23/2025 | 30.69% | Canaccord Genuity | $132 → $132 | Maintains | Buy | |||
10/22/2025 | 30.69% | BTIG | $132 → $132 | Reiterates | Buy → Buy | |||
10/17/2025 | 19.8% | Needham | $121 → $121 | Reiterates | Buy → Buy | |||
10/07/2025 | 8.91% | Evercore ISI Group | $115 → $110 | Maintains | Outperform | |||
10/02/2025 | 34.65% | Barclays | $133 → $136 | Maintains | Overweight | |||
10/01/2025 | 27.72% | Truist Securities | $125 → $129 | Maintains | Buy | |||
10/01/2025 | 30.69% | Canaccord Genuity | $131 → $132 | Maintains | Buy | |||
10/01/2025 | 26.73% | Baird | $123 → $128 | Maintains | Outperform | |||
10/01/2025 | 26.73% | Leerink Partners | $127 → $128 | Maintains | Outperform | |||
10/01/2025 | 19.8% | Needham | $121 → $121 | Reiterates | Buy → Buy | |||
10/01/2025 | 30.69% | BTIG | $127 → $132 | Maintains | Buy | |||
09/29/2025 | 23.76% | RBC Capital | $125 → $125 | Reiterates | Outperform → Outperform | |||
09/23/2025 | 25.74% | BTIG | $127 → $127 | Reiterates | Buy → Buy | |||
09/19/2025 | 19.8% | Needham | $121 → $121 | Reiterates | Buy → Buy | |||
09/11/2025 | 19.8% | Needham | $121 → $121 | Reiterates | Buy → Buy | |||
09/08/2025 | 23.76% | Oppenheimer | $118 → $125 | Upgrade | Perform → Outperform | |||
07/24/2025 | 33.66% | UBS | $130 → $135 | Maintains | Buy | |||
07/24/2025 | 22.77% | Raymond James | $121 → $124 | Maintains | Strong Buy | |||
07/24/2025 | 16.83% | Oppenheimer | $110 → $118 | Maintains | Perform | |||
07/24/2025 | 22.77% | Wells Fargo | $118 → $124 | Maintains | Overweight | |||
07/24/2025 | 23.76% | Truist Securities | $120 → $125 | Maintains | Buy | |||
07/24/2025 | 21.78% | Baird | $117 → $123 | Maintains | Outperform | |||
07/24/2025 | 31.68% | Barclays | $125 → $133 | Maintains | Overweight | |||
06/16/2025 | 16.83% | Leerink Partners | → $118 | Initiates | → Outperform | |||
05/28/2025 | 13.86% | Needham | $115 → $115 | Reiterates | Buy → Buy | |||
05/22/2025 | 23.76% | Citigroup | $119 → $125 | Maintains | Buy | |||
05/16/2025 | 23.76% | Morgan Stanley | $120 → $125 | Maintains | Overweight | |||
04/25/2025 | 23.76% | Barclays | $118 → $125 | Maintains | Overweight | |||
04/24/2025 | 19.8% | Raymond James | $122 → $121 | Maintains | Strong Buy | |||
04/24/2025 | 13.86% | Needham | $113 → $115 | Maintains | Buy | |||
04/24/2025 | 18.81% | RBC Capital | $116 → $120 | Maintains | Outperform | |||
04/24/2025 | 15.84% | Truist Securities | $113 → $117 | Maintains | Buy | |||
04/24/2025 | 10.89% | Evercore ISI Group | $110 → $112 | Maintains | Outperform | |||
04/24/2025 | 18.81% | Baird | $115 → $120 | Maintains | Outperform | |||
04/23/2025 | 22.77% | BTIG | $120 → $124 | Maintains | Buy | |||
04/16/2025 | 11.88% | Needham | → $113 | Upgrade | Hold → Buy | |||
04/11/2025 | 11.88% | Truist Securities | $120 → $113 | Maintains | Buy | |||
03/03/2025 | — | Needham | — | Reiterates | Hold → Hold | |||
02/10/2025 | 18.81% | Stifel | $115 → $120 | Maintains | Buy | |||
02/10/2025 | 16.83% | Barclays | $111 → $118 | Maintains | Overweight | |||
02/07/2025 | 28.71% | UBS | $105 → $130 | Maintains | Buy | |||
02/06/2025 | 18.81% | Truist Securities | $110 → $120 | Maintains | Buy | |||
02/06/2025 | 15.84% | Canaccord Genuity | $101 → $117 | Maintains | Buy | |||
02/06/2025 | 13.86% | Baird | $100 → $115 | Maintains | Outperform | |||
02/06/2025 | 20.79% | Raymond James | $119 → $122 | Maintains | Strong Buy | |||
02/06/2025 | 14.85% | RBC Capital | $105 → $116 | Maintains | Outperform | |||
02/06/2025 | 13.86% | Stifel | $100 → $115 | Maintains | Buy | |||
02/06/2025 | 16.83% | Wells Fargo | $100 → $118 | Maintains | Overweight | |||
02/06/2025 | 20.79% | Citigroup | $107 → $122 | Maintains | Buy | |||
02/06/2025 | 18.81% | Morgan Stanley | $100 → $120 | Maintains | Overweight | |||
02/06/2025 | — | Needham | — | Reiterates | Hold → Hold | |||
02/03/2025 | 13.86% | Piper Sandler | $95 → $115 | Maintains | Overweight | |||
01/31/2025 | 17.82% | Raymond James | $101 → $119 | Maintains | Strong Buy | |||
12/30/2024 | — | BTIG | $97 → $101 | Maintains | Buy | |||
12/18/2024 | 3.96% | RBC Capital | $98 → $105 | Maintains | Outperform | |||
12/18/2024 | 8.91% | Truist Securities | $100 → $110 | Maintains | Buy | |||
12/16/2024 | 8.91% | JP Morgan | $100 → $110 | Maintains | Overweight | |||
12/12/2024 | 8.91% | TD Cowen | $100 → $110 | Maintains | Buy | |||
12/11/2024 | 5.94% | Citigroup | $98 → $107 | Maintains | Buy | |||
12/11/2024 | -0.99% | Wells Fargo | $98 → $100 | Maintains | Overweight | |||
12/09/2024 | — | Canaccord Genuity | $98 → $101 | Maintains | Buy | |||
11/27/2024 | — | Needham | — | Reiterates | → Hold | |||
11/18/2024 | — | Needham | — | Reiterates | → Hold | |||
10/31/2024 | — | Needham | — | Reiterates | → Hold | |||
10/24/2024 | -0.99% | Bernstein | $92 → $100 | Maintains | Outperform | |||
10/24/2024 | -0.99% | Morgan Stanley | $92 → $100 | Maintains | Overweight | |||
10/24/2024 | -2.97% | RBC Capital | $95 → $98 | Maintains | Outperform | |||
10/24/2024 | -2.97% | Wells Fargo | $87 → $98 | Maintains | Overweight | |||
10/24/2024 | -2.97% | Citigroup | $92 → $98 | Maintains | Buy | |||
10/24/2024 | -2.97% | Canaccord Genuity | $98 → $98 | Maintains | Buy | |||
10/24/2024 | 8.91% | Mizuho | $100 → $110 | Maintains | Outperform | |||
10/24/2024 | — | Needham | — | Reiterates | → Hold | |||
10/23/2024 | -3.96% | BTIG | $93 → $97 | Maintains | Buy | |||
10/22/2024 | -0.99% | B of A Securities | $90 → $100 | Maintains | Buy | |||
10/21/2024 | -0.99% | TD Cowen | $86 → $100 | Maintains | Buy | |||
10/21/2024 | -2.97% | Canaccord Genuity | $88 → $98 | Maintains | Buy | |||
10/18/2024 | -0.99% | Stifel | $85 → $100 | Maintains | Buy | |||
10/18/2024 | -14.85% | Needham | $86 → $86 | Downgrade | Buy → Hold | |||
10/15/2024 | -0.99% | Baird | $91 → $100 | Maintains | Outperform | |||
10/14/2024 | -7.92% | BTIG | $84 → $93 | Maintains | Buy | |||
10/14/2024 | -0.99% | Truist Securities | $90 → $100 | Maintains | Buy | |||
10/08/2024 | -5.94% | RBC Capital | $85 → $95 | Maintains | Outperform | |||
10/01/2024 | -10.89% | Evercore ISI Group | $82 → $90 | Maintains | Outperform | |||
09/04/2024 | -6.93% | Raymond James | $91 → $94 | Maintains | Strong Buy | |||
08/22/2024 | -8.91% | Citigroup | $90 → $92 | Maintains | Buy | |||
08/22/2024 | -14.85% | Barclays | $78 → $86 | Maintains | Overweight | |||
07/25/2024 | -9.9% | Raymond James | $85 → $91 | Maintains | Strong Buy | |||
07/25/2024 | -22.77% | Deutsche Bank | $73 → $78 | Maintains | Hold | |||
07/25/2024 | -15.84% | RBC Capital | $85 → $85 | Reiterates | Outperform → Outperform | |||
07/25/2024 | -15.84% | JP Morgan | $82 → $85 | Maintains | Overweight | |||
07/25/2024 | -12.87% | Canaccord Genuity | $83 → $88 | Maintains | Buy | |||
07/25/2024 | -9.9% | Baird | $90 → $91 | Maintains | Outperform | |||
07/25/2024 | -14.85% | Needham | $82 → $86 | Maintains | Buy | |||
07/16/2024 | -14.85% | TD Cowen | $77 → $86 | Maintains | Buy | |||
07/16/2024 | -10.89% | Truist Securities | $86 → $90 | Maintains | Buy | |||
07/15/2024 | -16.83% | BTIG | $80 → $84 | Maintains | Buy |
FAQ
Quel est le cours indicatif de l'action Boston Scientific (BSX) ?
Le dernier objectif de prix pour Boston Scientific (NYSE:BSX) a été rapporté par UBS le octobre 23, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $140.00 s'attendant à ce que BSX se rise dans les 12 prochains mois (un possible changement de 38.61% upside). 68 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour Boston Scientific (BSX) ?
La dernière note d'analyste pour Boston Scientific (NYSE:BSX) a été fournie par UBS, et Boston Scientific maintenu leur note buy.
Quand a eu lieu la dernière mise à niveau pour Boston Scientific (BSX) ?
La dernière amélioration pour Boston Scientific Corp a eu lieu le septembre 8, 2025 lorsque Oppenheimer a augmenté leur objectif de prix à $125. Oppenheimer avait précédemment a perform pour Boston Scientific Corp.
Quand a eu lieu la dernière dégradation pour Boston Scientific (BSX) ?
La dernière réduction pour Boston Scientific Corp a eu lieu le octobre 18, 2024 lorsque Needham a changé leur objectif de prix de $86 à $86 pour Boston Scientific Corp.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour Boston Scientific (BSX) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de Boston Scientific, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour Boston Scientific a été déposée le octobre 23, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers octobre 23, 2026.
La note d'analyste pour Boston Scientific (BSX) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de Boston Scientific (BSX) était un maintenu avec un objectif de prix de $135.00 à $140.00. Le prix actuel de Boston Scientific (BSX) est de $101.00, ce qui est out of la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.